{
  "trials": [
    {
      "id": "NCT00000001",
      "drug": "Metformin",
      "indication": "Polycystic Ovary Syndrome (PCOS)",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Metformin evaluated for insulin-sensitizing effects and menstrual regulation in women with PCOS.",
      "results": "Improved ovulatory frequency and insulin sensitivity compared to placebo.",
      "start_date": "2010-01-15",
      "end_date": "2014-06-30"
    },
    {
      "id": "NCT00000002",
      "drug": "Metformin",
      "indication": "Breast Cancer (adjunct therapy)",
      "phase": "Phase 2",
      "status": "Active, not recruiting",
      "summary": "Evaluating metformin as adjuvant therapy to reduce recurrence in early-stage breast cancer patients with metabolic syndrome.",
      "results": "Preliminary signals of improved metabolic biomarkers; efficacy outcomes pending.",
      "start_date": "2018-05-01",
      "end_date": null
    },
    {
      "id": "NCT00000003",
      "drug": "Metformin",
      "indication": "Colorectal Cancer Prevention",
      "phase": "Phase 2",
      "status": "Completed",
      "summary": "Low-dose metformin given to high-risk patients to evaluate adenoma recurrence.",
      "results": "Reduced adenoma count in a subset of patients with hyperinsulinemia.",
      "start_date": "2012-03-10",
      "end_date": "2016-11-20"
    },
    {
      "id": "NCT00000004",
      "drug": "Aspirin",
      "indication": "Cardiovascular Disease Prevention",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Low-dose aspirin for primary prevention of cardiovascular events in high-risk patients.",
      "results": "Significant reduction in myocardial infarction risk, increased bleeding risk.",
      "start_date": "2005-03-15",
      "end_date": "2012-08-20"
    },
    {
      "id": "NCT00000005",
      "drug": "Aspirin",
      "indication": "Colorectal Cancer Prevention",
      "phase": "Phase 2",
      "status": "Active, recruiting",
      "summary": "Evaluating aspirin's anti-inflammatory effects on colorectal adenoma formation.",
      "results": "Interim analysis shows 20% reduction in adenoma formation.",
      "start_date": "2020-01-10",
      "end_date": null
    },
    {
      "id": "NCT00000006",
      "drug": "Sildenafil",
      "indication": "Pulmonary Arterial Hypertension",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Sildenafil citrate for treatment of pulmonary arterial hypertension in adults.",
      "results": "Improved exercise capacity and hemodynamic parameters.",
      "start_date": "2003-06-01",
      "end_date": "2005-12-15"
    },
    {
      "id": "NCT00000007",
      "drug": "Sildenafil",
      "indication": "Heart Failure with Preserved Ejection Fraction",
      "phase": "Phase 2",
      "status": "Terminated",
      "summary": "Investigating sildenafil for diastolic heart failure treatment.",
      "results": "No significant improvement in primary endpoints; study terminated.",
      "start_date": "2018-03-01",
      "end_date": "2020-11-30"
    },
    {
      "id": "NCT00000008",
      "drug": "Thalidomide",
      "indication": "Multiple Myeloma",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Thalidomide maintenance therapy in newly diagnosed multiple myeloma patients.",
      "results": "Significant improvement in progression-free survival.",
      "start_date": "2008-02-15",
      "end_date": "2014-07-30"
    },
    {
      "id": "NCT00000009",
      "drug": "Thalidomide",
      "indication": "Erythema Nodosum Leprosum",
      "phase": "Phase 2",
      "status": "Completed",
      "summary": "Thalidomide for severe erythema nodosum leprosum in leprosy patients.",
      "results": "Rapid and sustained improvement in skin lesions.",
      "start_date": "2015-09-01",
      "end_date": "2017-12-15"
    },
    {
      "id": "NCT00000010",
      "drug": "Hydroxychloroquine",
      "indication": "Rheumatoid Arthritis",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Hydroxychloroquine as disease-modifying antirheumatic drug in early RA.",
      "results": "Moderate improvement in joint symptoms and inflammation markers.",
      "start_date": "2010-04-20",
      "end_date": "2013-10-15"
    },
    {
      "id": "NCT00000011",
      "drug": "Hydroxychloroquine",
      "indication": "Systemic Lupus Erythematosus",
      "phase": "Phase 2",
      "status": "Active, recruiting",
      "summary": "Long-term hydroxychloroquine therapy for lupus flare prevention.",
      "results": "Ongoing study; preliminary data shows reduced flare frequency.",
      "start_date": "2021-06-01",
      "end_date": null
    },
    {
      "id": "NCT00000012",
      "drug": "Minoxidil",
      "indication": "Androgenetic Alopecia",
      "phase": "Phase 3",
      "status": "Completed",
      "summary": "Topical minoxidil for male and female pattern baldness treatment.",
      "results": "Significant hair regrowth in 65% of participants.",
      "start_date": "2016-01-15",
      "end_date": "2018-12-20"
    },
    {
      "id": "NCT00000013",
      "drug": "Minoxidil",
      "indication": "Alopecia Areata",
      "phase": "Phase 2",
      "status": "Completed",
      "summary": "Investigating minoxidil efficacy in patchy hair loss conditions.",
      "results": "Modest improvement; combination therapy shows promise.",
      "start_date": "2019-03-01",
      "end_date": "2021-08-30"
    }
  ]
}
